Eagle’s Eye View: Imaging Identifies HCM Patients at High-Risk of Adverse Outcomes
In this week’s View, Dr. Eagle reviews evidence supporting the use of cardiac magnetic resonance (CMR) and NT-proBNP in hypertrophic cardiomyopathy (HCM) risk assessment. He then examines the EXCALIBUR study, which aims to better characterize arrhythmic burden in patients with cardiac amyloidosis. Next, he discusses research identifying obesity as a significant risk factor for heart failure, highlighting key findings and clinical implications. Finally, he summarizes new evidence on the use of ivabradine and propranolol in treating postural orthostatic tachycardia syndrome (POTS).
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Arrhythmias and Clinical EP, Cardiac Surgery, Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Aortic Surgery, Cardiac Surgery and Arrhythmias, Cardiac Surgery and Heart Failure, Acute Heart Failure, Heart Failure and Cardiac Biomarkers, Heart Transplant, Mechanical Circulatory Support, Interventions and Imaging, Interventions and Structural Heart Disease, Acute Coronary Syndromes
Keywords: Magnetic Resonance Spectroscopy, Cardiomyopathy, Hypertrophic, Cardiac Imaging Techniques, Natriuretic Peptide, Brain, Gastrointestinal Hemorrhage, Heart Transplantation, Heart-Assist Devices, Bradycardia, Atrial Fibrillation, Heart Failure, Amyloidosis, Stroke, Obesity, Mortality, China, Blood Pressure, Postural Orthostatic Tachycardia Syndrome, Tachycardia, Testosterone, Menopause, Propranolol, EaglesEyeView
